We have applied the use of next-generation sequencing of whole genomes in fifty matched pretreatment tumor core biopsy specimens and blood normals resulting from a clinical trial of aromatase inhibitor therapy, from the American College of Surgeons Oncology Group (ACOSOG) Z1031 study. We also have studied the whole genomes of the post-treatment samples obtained from surgical resection, for additional comparison. We used additional accrued samples from this clinical trial to extend our findings. I will present our analysis of these data, including significantly mutated genes and pathways, the impact of aromatase inhibitor therapy on genomic heterogeneity, and integrated analyses to reveal a genomic signature predictive of aromatase inhibitor response.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr SY10-01. doi:10.1158/1538-7445.AM2011-SY10-01